title: Breast cancer treatment with imiquimod: applying an old lotion to a new disease.
abstract: Over the prior two decades, imiquimod, a toll-like receptor 7 agonist, has been applied to nearly 50 clinical settings. Because of its immunomodulatory role, the topical cream today, for the first time, is being applied to cutaneous breast cancer in preclinical models and in a phase II clinical trial.
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University Cancer Institute, Stanford, CA 94305, USA. holbrook.kohrt@gmail.com
authors.forename: Holbrook
authors.initials: H
authors.lastname: Kohrt
mesh_terms: D000634:Aminoquinolines / Q000008:administration & dosage*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D008562:Membrane Glycoproteins / Q000819:agonists*; D012878:Skin Neoplasms / Q000188:drug therapy*; D051199:Toll-Like Receptor 7 / Q000819:agonists* / Q000037:antagonists & inhibitors*
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; C495348:TLR7 protein, human; C477038:Tlr7 protein, mouse; D051199:Toll-Like Receptor 7; D000077271:Imiquimod